UBT251 Placebo

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2Type 2 diabetes (T2D)

Phase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

RecruitingNCT07668388

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2026-06-22End: 2027-11-15Target: 300Updated: 2026-08-10

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

Not yet recruitingCTIS2026-525465-42-00

Novo Nordisk A/SType 2 diabetes (T2D)

Target: 110Updated: 2026-09-01